Shopping Cart
- Remove All
Your shopping cart is currently empty
MYCi361
Catalog No. T12132Cas No. 2289690-31-7
Alias NUCC-0196361
MYCi361 (NUCC-0196361) is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM).
MYCi361
Catalog No. T12132Alias NUCC-0196361Cas No. 2289690-31-7
MYCi361 (NUCC-0196361) is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $118 | In Stock | |
| 5 mg | $287 | In Stock | |
| 10 mg | $457 | In Stock | |
| 25 mg | $753 | In Stock | |
| 50 mg | $1,060 | In Stock | |
| 100 mg | $1,430 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "MYCi361"
Nicotinamide N-oxide
Nicotinamide-N-oxide, Nicotinamide 1-oxide, 1-oxynicotinamide
T06171986-81-8
Nicotinamide N-oxide (Nicotinamide 1-oxide) is recognized as an in vivo metabolite of nicotinamide which is a precurser of nicotinamide-adenine dinucleotide (NAD+) in animals. The enzyme that catalyzes the reduction of nicotinamide N-oxide to nicotinamide in the liver is xanthine oxidase.
- $33
Size
QTY
VPC-70063
Thiourea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-(phenylmethyl)-
T6001913571-44-3
VPC-70063 (Thiourea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-(phenylmethyl)-) is an inhibitor of c-Myc-MAX. VPC-70063 exhibits Myc-Max transcriptional activity inhibition of 106% with an IC50 of 8.9 μM and Myc-Max/UBE2C downstream pathway inhibition of 94%. VPC-70063 can be used for studies about anticancer.
- $47
Size
QTY
MYCi975
NUCC-0200975
T121332289691-01-4
MYCi975 (NUCC-0200975) is an orally active MYC inhibitor.
- $127
Size
QTY
10058-F4
Cited
c-Myc Inhibitor
T3048403811-55-2
10058-F4 (c-Myc Inhibitor) is a cell-permeable thiazolidinone that specifically inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression; induces cell-cycle arrest and apoptosis.
- $43
Size
QTY
CitedBTYNB
MDK6620, BTYNB IMP1 Inhibitor
T9033304456-62-0
BTYNB (MDK6620) is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA). MDK6620 downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB). It disrupts this enhancer function by impairing IGF2 mRNA-binding protein 1 (IGF2BP1)-RNA association
- $40
Size
QTY
EN4
EN4 MYC inhibitor
T90611197824-15-9
EN4 (EN4 MYC inhibitor) MYC inhibitor is a covalent ligand that targets cysteine 171 (C171) of MYC. It is selective for c-MYC over N-MYC and L-MYC, and inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis.
- $32
Size
QTY
Mycro 3
Mycro-3
T4367944547-46-0
Mycro 3 is potent and selective for c-Myc in whole cell assays.
- $75
Size
QTY
10074-A4 Cited
T9628312631-87-1
10074-A4 is a c-Myc binding compound that associates with c-Myc[370–409] and acts as a “ligand cloud” around a “protein cloud”, exhibiting distinct characteristics compared to a non-binding ligand.
- $65
Size
QTY
CitedMYCMI-6
NSC354961
T12134681282-09-7
MYCMI-6 (NSC-354961) is a potent and selective inhibitor of endogenous MYC:MAX protein interactions，reduces proliferation and induces massive apoptosis in tumor tissue from a MYC-driven xenograft tumor model without severe side effects.
- $68
Size
QTY
Select Batch
Purity:99.52%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | MYCi361 (NUCC-0196361) is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM). |
| Targets&IC50 | MYC:3.2 μM(Kd) |
| In vitro | MYCi361 is a small-molecule MYC inhibitors that inhibits the viability of MYC-dependent cancer cells including prostate cancer (MycCaP, LNCaP, and PC3), leukemia (MV4-11), lymphoma (HL-60 and P493-6), and neuroblastoma (SK-N-B2) with low-micromolar IC50 values[1]. |
| In vivo | MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. |
| Animal Research | FVB or NSG male mice of 6-8 weeks of age and 25 g bearing established MycCaP tumors.MYCi361 treatment i.p. initially at 50 mg/kg twice daily for 2 days, then 70 mg/kg/day for 9 days |
| Alias | NUCC-0196361 |
| Molecular Weight | 594.86 |
| Formula | C26H16ClF9N2O2 |
| Cas No. | 2289690-31-7 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (168.1 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy MYCi361 | purchase MYCi361 | MYCi361 cost | order MYCi361 | MYCi361 chemical structure | MYCi361 in vivo | MYCi361 in vitro | MYCi361 formula | MYCi361 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.